Francesco Hofmann

Francesco Hofmann

UNVERIFIED PROFILE

Are you Francesco Hofmann?   Register this Author

Register author
Francesco Hofmann

Francesco Hofmann

Publications by authors named "Francesco Hofmann"

Are you Francesco Hofmann?   Register this Author

57Publications

2521Reads

17Profile Views

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

Cell 2017 Jul;170(3):577-592.e10

Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.07.005DOI Listing
July 2017

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Mol Cancer Ther 2014 May 7;13(5):1117-29. Epub 2014 Mar 7.

Authors' Affiliations: Novartis Institutes for BioMedical Research, Disease Area Oncology; Novartis Institutes for BioMedical Research, Global Discovery Chemistry; Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry; Novartis Pharma AG, Oncology Translational Medicine, Basel, Switzerland; Novartis Pharma AG, Oncology Translational Medicine; Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Cambridge, Massachusetts; and Novartis Institutes for BioMedical Research, Developmental and Molecular Pathways, Shangai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0865DOI Listing
May 2014

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

Clin Cancer Res 2013 Nov 30;19(22):6230-41. Epub 2013 Sep 30.

Authors' Affiliations: Disease Area Oncology and Preclinical Safety, Discovery and Investigative Pathology, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0905DOI Listing
November 2013

The path to oncology drug target validation: an industry perspective.

Methods Mol Biol 2013 ;986:3-13

Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2F978-1-62703-3
Web Search
http://link.springer.com/10.1007/978-1-62703-311-4_1
Publisher Site
http://dx.doi.org/10.1007/978-1-62703-311-4_1DOI Listing
August 2013

The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.

Chembiochem 2013 Jul 18;14(10):1218-25. Epub 2013 Jun 18.

Disease Area Oncology, Novartis Institutes for Biomedical Research, 141 Klybeckstrasse, 4057 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbic.201300163DOI Listing
July 2013

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.

Proc Natl Acad Sci U S A 2013 Jan 24;110(2):489-94. Epub 2012 Dec 24.

Disease Area Oncology, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1212780110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545759PMC
January 2013

Acentrosomal spindle organization renders cancer cells dependent on the kinesin HSET.

J Cell Sci 2012 Nov 3;125(Pt 22):5391-402. Epub 2012 Sep 3.

NIBR Oncology Disease Area, Novartis Pharma AG, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/jcs.107474DOI Listing
November 2012

Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.

Mol Cancer Res 2012 Jun 4;10(6):800-9. Epub 2012 May 4.

Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Mattenstrasse 28, Basel 4058, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-11-0522DOI Listing
June 2012

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Cancer Res 2006 Feb;66(3):1500-8

Program in Molecular Pharmacy and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-2925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193604PMC
February 2006

High-throughput assay to monitor formation of the E2-ubiquitin thioester intermediate.

Methods Enzymol 2005 ;398:87-100

Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0076-6879(05)98009-9DOI Listing
December 2005

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.

Drug Discov Today 2005 Aug;10(15):1041-7

Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1359-6446(05)03512-9DOI Listing
August 2005

The human ubiquitin-conjugating enzyme Cdc34 controls cellular proliferation through regulation of p27Kip1 protein levels.

Exp Cell Res 2005 Feb;303(2):482-93

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Disease Area Oncology, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2004.10.008DOI Listing
February 2005

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.

Clin Cancer Res 2005 Feb;11(4):1563-71

Department of Medicine, Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1544DOI Listing
February 2005

Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching.

Bioorg Med Chem Lett 2003 Sep;13(18):2967-71

Oncology Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(03)00626-7DOI Listing
September 2003

Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage.

Mol Cell 2003 Sep;12(3):735-46

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1097-2765(03)00355-1DOI Listing
September 2003